We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
-9.86%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$16.1B
AUM Growth
-$2.79B
(-15%)
Cap. Flow
-$319M
Cap. Flow
% of AUM
-1.98%
Top 10 Holdings %
Top 10 Hldgs %
25.53%
Holding
844
New
146
Increased
323
Reduced
295
Closed
69
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Valero Energy
VLO
|
+$111M |
| 2 |
Kinder Morgan
KMI
|
+$108M |
| 3 |
WLL
Whiting Petroleum Corporation
WLL
|
+$101M |
| 4 |
IAMGOLD
IAG
|
+$80.8M |
| 5 |
Hecla Mining
HL
|
+$78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GG
Goldcorp Inc
GG
|
+$221M |
| 2 |
B
Barrick Mining
B
|
+$188M |
| 3 |
Newmont
NEM
|
+$130M |
| 4 |
ANDV
Andeavor
ANDV
|
+$118M |
| 5 |
Franco-Nevada
FNV
|
+$109M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 43.59% |
| 2 | Energy | 24.2% |
| 3 | Healthcare | 6.87% |
| 4 | Industrials | 4.15% |
| 5 | Technology | 3.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MHG
151
DELISTED
Marine Harvest ASA
MHG
| $16.8M | 0.1% |
+1,231,859
| New | +$17.2M |
|
|
PCYC
152
DELISTED
PHARMACYCLICS INC
PCYC
| $16.8M | 0.1% |
137,457
-20,535
| -13% | -$2.62M |
|
|
DO
153
DELISTED
Diamond Offshore Drilling
DO
| $16.7M | 0.1% |
455,880
+57,504
| +14% | +$2.06M |
|
154
Idexx Laboratories
IDXX
$42.9B
| $16.5M | 0.1% |
222,644
-40,242
| -15% | -$2.82M |
|
|
SVM
155
Silvercorp Metals
SVM
$2.13B
| $16.4M | 0.1% |
12,625,712
-12,490,590
| -50% | -$17.4M |
|
156
Broadcom
AVGO
$1.82T
| $16.4M | 0.1% |
1,627,680
-188,050
| -10% | -$1.68M |
|
|
EXK
157
Endeavour Silver
EXK
$2.32B
| $16.3M | 0.1% |
7,534,541
-7,913,228
| -51% | -$24.4M |
|
158
Sanofi
SNY
$104B
| $16.3M | 0.1% |
356,814
-46,403
| -12% | -$2.25M |
|
159
NXP Semiconductors
NXPI
$68B
| $16.1M | 0.1% |
+211,228
| New | +$15M |
|
160
GSK
GSK
$103B
| $16.1M | 0.1% |
301,008
-38,521
| -11% | -$2.16M |
|
161
AbbVie
ABBV
$458B
| $15.8M | 0.1% |
242,138
-73,642
| -23% | -$4.64M |
|
162
Analog Devices
ADI
$181B
| $15.7M | 0.1% |
282,433
-32,474
| -10% | -$1.66M |
|
163
Merck
MRK
$324B
| $15.5M | 0.1% |
285,911
-129,081
| -31% | -$7.19M |
|
164
Ionis Pharmaceuticals
IONS
$9.35B
| $15.2M | 0.09% |
246,868
+29,062
| +13% | +$1.43M |
|
|
NVO
165
Novo Nordisk
NVO
$216B
| $15.1M | 0.09% |
714,878
-158,508
| -18% | -$3.54M |
|
166
McEwen Inc
MUX
$1.03B
| $15.1M | 0.09% |
1,362,326
-2,774,524
| -67% | -$38.9M |
|
|
AGN
167
DELISTED
Allergan Inc
AGN
| $15M | 0.09% |
70,561
-20,477
| -22% | -$4.07M |
|
168
Abbott
ABT
$180B
| $14.9M | 0.09% |
331,917
-89,051
| -21% | -$3.88M |
|
169
Bristol-Myers Squibb
BMY
$127B
| $14.7M | 0.09% |
248,435
-105,116
| -30% | -$5.93M |
|
170
Home Depot
HD
$332B
| $14.6M | 0.09% |
139,125
+81,270
| +140% | +$7.89M |
|
|
WLB
171
DELISTED
Westmoreland Coal Company
WLB
| $14.6M | 0.09% |
439,700
-13,700
| -3% | -$479K |
|
|
RDC
172
DELISTED
Rowan Companies Plc
RDC
| $14.6M | 0.09% |
625,534
+51,030
| +9% | +$1.18M |
|
173
Eli Lilly
LLY
$1.07T
| $14.4M | 0.09% |
208,895
-60,963
| -23% | -$4.11M |
|
174
AstraZeneca
AZN
$263B
| $14.1M | 0.09% |
200,016
-41,747
| -17% | -$2.99M |
|
|
CVD
175
DELISTED
COVANCE INC.
CVD
| $13.7M | 0.09% |
131,647
+12,984
| +11% | +$1.22M |
|
Similar funds
DAM
VanEck Associates's Q4 2014 Portfolio in Review
As of Q4 2014, VanEck Associates held 844 positions worth $16.1B, down 15% from $18.9B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
VanEck Associates's Q4 2014 filing shows 146 new, 323 increased, 295 reduced and 69 closed positions. Its largest new stake was Allergan plc: 238,299 shares worth $61.3M. The largest sale was Goldcorp Inc, an estimated $221M.
By sector, the portfolio is most concentrated in Materials at 44% of assets, down from 45% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q4 2014 buy was Allergan plc: 238,299 shares worth $61.3M.
- VanEck Associates added most to Valero Energy in Q4 2014, an estimated $111M increase.
- VanEck Associates's biggest Q4 2014 reduction was Goldcorp Inc, cutting an estimated $221M.
- VanEck Associates fully exited Atwood Oceanics in Q4 2014, selling an estimated $101M.
- VanEck Associates's ten largest holdings make up 26% of its $16.1B portfolio in Q4 2014.
- VanEck Associates opened 146 new positions and closed 69 in Q4 2014.
- VanEck Associates's portfolio value fell 15% quarter-over-quarter to $16.1B.
Based on VanEck Associates's 13F filing for Q4 2014, filed 13 Feb 2015.